WINTON GROUP Ltd grew its stake in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 164.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,688 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,717 shares during the period. WINTON GROUP Ltd’s holdings in Supernus Pharmaceuticals were worth $1,193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. FMR LLC raised its holdings in shares of Supernus Pharmaceuticals by 1,909.6% during the second quarter. FMR LLC now owns 941,300 shares of the specialty pharmaceutical company’s stock valued at $56,337,000 after purchasing an additional 894,459 shares during the period. BlackRock Inc. raised its holdings in shares of Supernus Pharmaceuticals by 8.7% in the 2nd quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock worth $460,287,000 after acquiring an additional 618,722 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Supernus Pharmaceuticals by 191.3% in the 2nd quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock worth $52,949,000 after acquiring an additional 580,990 shares during the last quarter. Voya Investment Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 933.5% in the 2nd quarter. Voya Investment Management LLC now owns 585,319 shares of the specialty pharmaceutical company’s stock worth $35,031,000 after acquiring an additional 528,685 shares during the last quarter. Finally, Castleark Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth about $18,065,000. Hedge funds and other institutional investors own 98.30% of the company’s stock.

SUPN opened at $45.11 on Wednesday. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals Inc has a fifty-two week low of $34.90 and a fifty-two week high of $61.25. The stock has a market capitalization of $2.33 billion, a P/E ratio of 35.80 and a beta of 0.92.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.09. The firm had revenue of $102.99 million during the quarter, compared to analyst estimates of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. Equities analysts forecast that Supernus Pharmaceuticals Inc will post 1.87 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on SUPN shares. Piper Jaffray Companies restated a “hold” rating and issued a $44.00 target price on shares of Supernus Pharmaceuticals in a report on Thursday, August 9th. Cantor Fitzgerald set a $57.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Mizuho started coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 target price on the stock. Finally, B. Riley lowered their target price on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating on the stock in a report on Monday. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $56.00.

WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/11/14/winton-group-ltd-increases-stake-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

See Also: Stock Split

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.